AstraZeneca CEO joins Agilent Board
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AstraZeneca PLC ADR (AZN)
AstraZeneca PLC ADR stock price live, this page displays NASDAQ AZN stock exchange data. View the AZN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AstraZeneca PLC ADR real time stock price chart below.
What Is the AstraZeneca PLC ADR Stock Price Today?
The AstraZeneca PLC ADR stock price today is 69.68.
What Is the Stock Symbol for AstraZeneca PLC ADR?
The stock symbol for AstraZeneca PLC ADR is "AZN."
What Stock Exchange Does AstraZeneca PLC ADR Trade On?
AstraZeneca PLC ADR is listed and trades on the NASDAQ stock exchange.
Is AstraZeneca PLC ADR a Good Stock to Buy?
Determining whether AstraZeneca PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AZN quote. (ISIN: US0463531089)
What Is the AstraZeneca PLC ADR Stock Price Today?
The AstraZeneca PLC ADR stock price today is 69.68.
What Is the Stock Symbol for AstraZeneca PLC ADR?
The stock symbol for AstraZeneca PLC ADR is "AZN."
What Stock Exchange Does AstraZeneca PLC ADR Trade On?
AstraZeneca PLC ADR is listed and trades on the NASDAQ stock exchange.
Is AstraZeneca PLC ADR a Good Stock to Buy?
Determining whether AstraZeneca PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AZN quote. (ISIN: US0463531089)
NASDAQ
Symbol | Exchange | Currency | |||
|---|---|---|---|---|---|
| AZN | · | NASDAQ | · | USD | |
| AZNl | · | BATS Europe | · | GBP | |
| AZNs | · | BATS Europe | · | SEK | |
| AZNCF | · | OTC Markets | · | USD | |
| 3SAZ | · | London | · | GBP | |
| 3LAZ | · | London | · | GBP | |
| AZN | · | London | · | GBP | |
| AZNN | · | Mexico | · | MXN | |
| AZNN | · | BIVA | · | MXN | |
| AZN | · | Stockholm | · | SEK | |
| AZN | · | TradeGate | · | EUR | |
| AZN | · | Xetra | · | EUR | |
| AZNPy | · | TradeGate | · | EUR | |
| AZN | · | Frankfurt | · | EUR | |
| AZNPy | · | Frankfurt | · | EUR | |
| AZNm | · | Buenos Aires | · | ARS | |
| A1ZN34 | · | B3 | · | BRL | |
| AZNA | · | Vienna | · | EUR |
Currency in USD
69.68
-0.24(-0.34%)
Closed·
After Hours
69.58-0.10(-0.15%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
69.57
70.98
52 wk Range
61.24
87.68
AZN Scorecard
Full Analysis
2 analysts have revised their earnings downwards for the upcoming period
AZN is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
69.5770.98
52 wk Range
61.2487.68
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.18%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.18%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AZN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
84.60
Upside
+21.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
- AstraZeneca reveals positive results from BATURA Phase 3b trial
- Investing.com
Pro
- AstraZeneca CEO joins Agilent Board
- Investing.com
AstraZeneca PLC ADR Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC ADR SWOT Analysis
Oncology Powerhouse | AstraZeneca's robust oncology portfolio and pipeline drive growth, with key drugs like Enhertu and Imfinzi showing promising results in various cancer treatments |
Financial Strength | Raised guidance for 2024 reflects confidence, with total revenue and core earnings expected to grow in mid-teens percentage at constant exchange rates |
Strategic Expansion | Explore AstraZeneca's moves into earlier treatment lines and new therapeutic modalities, including antibody-drug conjugates and CAR-T cell therapies |
Market Valuation | Analysts set price targets ranging from $82 to $89, with AstraZeneca appearing undervalued based on InvestingPro's Fair Value analysis |
Compare AZN to Peers and Sector
Metrics to compare | AZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.1x | 18.0x | −0.5x | |
PEG Ratio | 1.23 | 0.05 | 0.00 | |
Price/Book | 5.3x | 3.1x | 2.6x | |
Price / LTM Sales | 4.0x | 2.4x | 3.0x | |
Upside (Analyst Target) | 22.3% | 5.2% | 48.7% | |
Fair Value Upside | Unlock | 28.1% | 9.2% | Unlock |
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 84.60
(+21.41% Upside)
Earnings
Latest Release
Apr 29, 2025
EPS / Forecast
2.49 / 1.10
Revenue / Forecast
13.59B / 13.77B
People Also Watch
FAQ
What Is the AstraZeneca ADR (AZN) Stock Price Today?
The AstraZeneca ADR stock price today is 69.68
What Stock Exchange Does AstraZeneca ADR Trade On?
AstraZeneca ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for AstraZeneca ADR?
The stock symbol for AstraZeneca ADR is "AZN."
Does AstraZeneca ADR Pay Dividends? What’s The Current Dividend Yield?
The AstraZeneca ADR dividend yield is 2.18%.
What Is the AstraZeneca ADR Market Cap?
As of today, AstraZeneca ADR market cap is 219.07B.
What Is AstraZeneca ADR's Earnings Per Share (TTM)?
The AstraZeneca ADR EPS (TTM) is 5.01.
When Is the Next AstraZeneca ADR Earnings Date?
AstraZeneca ADR will release its next earnings report on 23 July 2025.
From a Technical Analysis Perspective, Is AZN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has AstraZeneca ADR Stock Split?
AstraZeneca ADR has split 2 times.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.